COVID-19 Funding

This page is updated daily, providing the University Research Community with information about funding opportunities related to the novel coronavirus (COVID-19). Please contact Lynette Michael with questions or to notify of additional COVID-19-related funding sources.

Note that "new to this day" opportunities are at the top of the table and denoted as NEW. Opportunities are ordered in the table by Sponsor Name.

Opportunities current as of April 16, 2021


DEADLINE(S)SPONSOROPPORTUNITY TITLE/LINKADDITIONAL INFORMATION

August 17, 2021

NIAAA has added a deadline for these RFAs

UPDATED (04/16/21)

National Institute on Alcoholism and Alcohol Abuse (NIAAA)

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use

R01 (RFA-AA-21-002)

R03 (RFA-AA-21-003)

R21 (RFA-AA-21-004)

NIAAA is requesting applications focusing on relationships between alcohol consumption and COVID-19 outcomes. Grant mechanisms offered are the Research Project Grant (R01), Small Grant (R03) and Exploratory/Developmental Grants (R21).

July 16, 2021

23andMeResearch Innovation CollaborationsThe sponsor is conducting ongoing research pertaining to COVID-19 within their customer base. They encourage academic researchers to consider collaborating with company scientists through this program.

Deadlines dependent on chosen funding mechanism; this SEN expires March 15, 2023

Agency for Healthcare Research and Quality (AHRQ)Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic (NOT-HS-21-010)AHRQ is offering an opportunity for health services researchers to propose research projects addressing the US substance use disorder crisis. Within this context, AHRQ is very interested in receiving applications that use the current COVID-19 pandemic as a natural experiment to discover how COVID-19 related changes in health care delivery (e.g., increase in telehealth usage) affected access to care, quality of care and health inequities. Multiple grant mechanisms are offered.
Required Letters of Intent due February 18, 2021; invited full applications are then due April 30, 2021American Lung Association (ALA)COVID-19 and Emerging Respiratory Viruses Research AwardsALA will support clinical, basic, translational and population health research projects related to: 1) A new understanding of the basic biology of respiratory viruses that could lead to better treatment and prevention; 2) Understanding host factors that alter response to these infections; 3) Understanding individual, regional or social factors increasing or decreasing community spread of COVID-19 and other respiratory viruses; and 4) Case tracking and epidemiological approaches to understanding COVID-19 and other respiratory viruses.
Continuous submissionArgonne National Laboratory (US Department of Energy)Expedited, Rapid Access Call for COVID-19 Research SupportThe Advanced Photon Source at Argonne is offering remote access to beamlines for macromolecular crystallography and BioSAXS for research efforts related to SARS-CoV-2 or COVID-19.
No deadline specifiedBoehringer IngelheimInvestigator-Initiated Studies (IIS): Established ProductsThe sponsor's purpose is to evaluate potential clinical and non-clinical investigations involving COVID-19 related matters including safety, clinical outcomes, antiviral effects or antithrombotic benefits.
Continuous submissionBrookhaven National Laboratory (US Department of Energy)COVID-19 Research SupportThe Center for Biomolecular Structure is supporting remote macromolecular crystallography experiments at the AMX and FMX beamlines and solution scattering experiments at the LiX beamline for COVID-19 research.
Applications accepted on a rolling basis (open until sponsor meets program goals)CISCO Systems, Inc.Contactless Supply Chain (RFP-21-06)Noting that COVID-19 among other factors has placed emphasis on the need for profound transformation of supply chains, CISCO welcomes both technical and business-related projects.
Proposals may be submitted any time; note that interested researchers should respond quickly as Cisco withdraws RFPs when they determine they have met the program goal.CISCO Systems, Inc.

Future of Work (RFP-21-02)

In light of COVID-19 and the new reality of working from home indefinitely that the pandemic has brought us, Cisco Research Center has released this RFP to encourage research aimed at making the remote work environment more ideal.
Continuous submission until closed by sponsorCISCO Systems, Inc.

Tech for Healthcare (RFP-21-04)

 
Cisco is interested in funding research related to applications of technology for health care purposes. Pandemic related sponsor interests include sensor technologies, scalable monitoring of public health protocols such as mask wearing, systems for scalable contact tracing and many others.
Applications accepted anytime until funds are depleted for the yearComcastInnovation Fund: Research GrantsComcast is interested in receiving proposals related to COVID-19 effects on the Internet among other topics.
Deadlines for these programs will be set in the program announcement, due out soonCongressionally Directed Medical Research Program (CDMRP)DOD Multiple Sclerosis Research ProgramCDMRP has issued a pre-announcement for various funding mechanisms including the Early Investigator Research Award (targeting postdoctoral and clinical fellows), the Exploration-Hypothesis Development Award and the Investigator-Initiated Research Award, that will support research on the interactions between multiple sclerosis and COVID-19.
Applications accepted on rolling basisCOVID-19 Early Treatment Fund (CETF)Grants ProgramAdvocating early, effective treatment for COVID-19 patients designed to prevent hospitalization, CETF is supporting outpatient clinical trials of re-purposed antiviral drugs. 
Continuous submissionDepartment of Energy
(US DOE)
Dear Colleague Letter - Corona Virus Disease 2019 (COVID-19)DOE is encouraging submission of scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure.
Continuous submissionDepartment of Energy (DOE)Rapid Access for COVID-19 ResearchDOE is offering remote access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapeutics.
October 31, 2021 
(this is final white paper submission deadline; full proposals will be invited by the sponsor)
Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA)Broad Agency Announcement (BAA)BARDA has updated this BAA to reflect its current Areas of Interest (AOI), all related to COVID-19: 
AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms; 

AOI 7.7.2 Point-of-care diagnostic assay for  detection of SARS-CoV-2 virus; 
AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
AOI 9.2 COVID-19 Therapeutics
AOI 17 Advanced Manufacturing Technologies

 

February 3, 2023 or until rescinded for AOI #1, AOI #2 and AOI #6

June 30, 2021 for required abstracts addressing AOI #7

Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA)

Division of Research Innovations and Ventures Easy Broad Agency Announcement (DRIVe)

See DRIVe EZ BAA Special Instructions 012 for details on AOI #1, AOI #2 and AOI #6

See Special Instructions 13 for AOI #7

BARDA has added an Area of Interest (AOI) titled "ImmuneChip+" (AOI #7, 03/04/2021) seeking add-ons to existing, validated in vitro human tissue (e.g., lung, liver, gut or heart) models that address immune system responsiveness and/or a viral, bacterial or fungal pathogen. Proposed use cases may, but are not required, to center on infection of the human lung with a pathogen such as influenza or SARS-CoV-2.

An update from 10/22/20 indicates the sponsor has added AOIs to the Broad Agency Announcement that can relate to, but are not specific to, COVID-19: AOI #1 - Early Notification to Act, Control and Treat (ENACT); AOI #2 - Infection Severity and Solving Sepsis; and AOI #6 - Beyond the Needle.

Continuous SubmissionDiamond Light SourceRapid Access Call for Proposals: SARS-CoV-2Diamond, the UK's national synchotron, is offering its facilities and fragment screening expertise to researchers world-wide who are working on COVID-19 related projects.
Applications accepted on rolling basisEmergent VenturesFast Grants for COVID-19The sponsor provides funding for researchers at academic institutions who are currently working on scientific or biomedical COVID-19 projects that could help with the pandemic within the next 6 months. Funding decisions are promised within 14 days for this second round of funding. This grant program is administered by the Mercatus Center at George Mason University.
May 7, 2021Environmental Protection Agency (EPA)Environmental Justice Collaborative Problem-Solving Cooperative Agreement Program (EOA-OP-OEJ-21-02)Note that this program targets community-based organizations as lead institutions, but encourages partnerships with local stakeholder groups including academia. Projects focused on COVID-19 impacts in low-income communities and communities of color will be prioritized for this year's program as will work on climate and disaster resiliency.
Applications accepted on a rolling basisEuro Bio-ImagingFast Track Access to Biological and Biomedical Imaging Technologies for COVID-19 Research ProjectsScientists worldwide with ongoing COVID-19 research projects in need of imaging resources will want to consider this opportunity. The sponsor is offering to facilitate access to over 40 biological and biomedical imaging technologies, supporting basic research efforts as well as medical applications and diagnostics.
Continuous submissionExtreme Science and Engineering Discovery Environment (XSEDE)
(funded by the National Science Foundation)
COVID-19 HPC Consortium

This Consortium houses some of the most powerful and advanced computers in the world which will be made available to researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections.

No deadlineFacebookCrowdTangle Public Application for AcademicsUsing Facebook's CrowdTangle, designed to enhance abilities to follow, analyze and report on what's happening across social media, this opportunity will allow researchers to gain access to CrowdTangle tools/technical support. Projects should be focused on misinformation, elections, COVID-19, racial justice and/or well-being. Applications are for access to CrowdSource; no funding is associated with this opportunity.
No deadlinesFacebookNew Preventive Health Survey Data Available for ResearchFacebook has partnered with the Massachusetts Institute for Technology (MIT) Initiative on the Digital Economy and Johns Hopkins University Center for Communication Programs to launch a Preventive Health Survey, designed to assess the public's knowledge, attitude and practices about COVID-19 prevention. Researchers are invited to request aggregated, de-identified survey data; access to  microdata may also be requested but requires a signed data use agreement.
None indicatedFacebookSymptom SurveysFacebook is offering access to survey data collected on a national and global level concerning Facebook users and COVID-19 symptoms. The Symptom Survey datasets are managed by Carnegie Mellon University and the University of Maryland. Academic and non-profit researchers may request access to the aggregated survey data. See the website for more details on survey methodology and the process for requesting data access.
Not accepting applications at this time; the agency has additional funding for FY21, but must resolve several issues before opening for applicationsFederal Communications Commission (FCC)COVID-19 Telehealth ProgramAvailable funding of $200 million for this program comes from the recently enacted CARES Act. It's designed to pay eligible health care providers (to include postsecondary educational institutions offering health care instruction, teaching hospitals and medical schools) to provide connected care services for patients by funding telecommunications services, information services and necessary devices. This is not a grant program; instead, after initial approval, provider expenses related to COVID-19 telehealth services for patients will be reimbursed (starting with expenses incurred after March 13, 2020).
May 14, 2021Fogarty International Center (FIC) (NIH)Notice of Special Interest (NOSI): Administrative Supplements for COVID-19 Impacted FIC Research Training and Education Awards (NOT-TW-21-003)FIC will provide supplements to training and education awards (D43, U2R, R25) that are in their last year of funding and have been significantly affected by the COVID-19 pandemic.
May 14, 2021Fogarty International Center (FIC) (NIH)Notice of Special Interest (NOSI): Administrative Supplements to FIC Awards for COVID-19-related Research in Low-and-Middle-Income Countries (NOT-TW-21-004)Supplemental funding for active FIC awards is available to support COVID-19-related research or mentored research projects on scientific questions unique to low-and-middle-income countries (LMICs).
Submissions will be uploaded on the FIND website on a rolling basisFoundation for Innovative New Diagnostics (FIND)Open Call for Data - COVID-19

This Switzerland-based non-profit is asking laboratories around the world with any performance data on commercially available in vitro diagnostic tests that detect nucleic acid, viral antigen or antibodies to contribute to a centralized collection of data as a global public good. The data compilation will be made available on the FIND website to enable fast data sharing throughout the diagnostic community. 

No deadline indicatedGinkgo BioworksAccess to Platform for Partner COVID-19 ProjectsThe sponsor is offering access to its platform for company and academic labs engaged in developing a diagnostic, drug or vaccine to stop COVID-19.
Ongoing review

William T. Grant Foundation

Spencer Foundation

Rapid Response Research GrantsThe Grant Foundation will use the Rapid Response Research Grants mechanism to fund projects designed to combat youth inequality in the US, a main priority of the Foundation, made worse by the COVID-19 Pandemic. They are joined by the Spencer Foundation in this endeavor. These grants will fund collaborations between researchers and policymakers. Researchers on the team synthesize relevant literature within 6-8 weeks from the start of the grant award, and work with their policy partners to ensure the research results in actions benefiting youth.
Phase 1 Brief Proposals may be submitted anytime; full proposals will be invited by the sponsorRobert Wood Johnson Foundation (RWJF)Pioneering Ideas: Exploring the Future to Build a Culture of HealthRWJF is looking for future-focused projects in four focus areas to benefit their overall Foundation theme - Building a Culture of Health: 1) Future of Evidence, 2) Future of Social Interaction, 3) Future of Food and 4) Future of Work. Emphasis is on health equity. The sponsor notes that while this opportunity is focused on broader trends evolving prior to COVID-19, they are open to projects addressing the pandemic, either directly or indirectly.
Continuous submission (contact program officer first)National Cancer Institute (NCI)Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-Supported Projects to be Redirected to COVID-1-Related Research during the CrisisNCI-funded researchers who wish  to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship may request variance to use a portion of their NCI project funds to address this crisis.
Applications accepted on a rolling basis from May 15, 2020 through January 25, 2022National Center for Advancing Translational Sciences (NCATS)Notice of Special Interest regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel CoronavirusNCATS is interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and then advance the translation of research findings into diagnostics, therapeutics, and vaccines.
Applications accepted on rolling basis from May 15, 2020 to January 25, 2022National Center for Advancing Translational Sciences (NCATS)Notice of Special Interest regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel CoronavirusNCATS is interested in three specific topics: 1) Incorporation of new and emerging data related to SARS-CoV-2 into ongoing research efforts to develop microphysiological systems/tissue chips models for COVID-19; 2) Use of microphysiological systems/tissue chips or evaluating, repurposing or modification of diagnostic tools to enable rapid detection of COVID-19 infection; and 3) Use of microphysiological systems/tissue chips for the rapid development and assessment of potential therapeutic agents for COVID-19
May 1, 2021National Center for Farmworker HealthRequest for Proposals - Reducing the Impact of COVID-19 on Farmworker FamiliesThe program goal is to protect and support farmworkers and their families concerning COVID-19. Proposals that focus on harder-to-reach populations (e.g., communities of indigenous farmworkers, H-2A guest workers, farmworkers living in congregate housing and/or working in extremely remote areas) will be prioritized. Activities supported are vaccination, testing/quarantine, treatment and reinforcement of safety precautions.
Applications are due beginning with the October 5, 2020 deadline; this NOSI will expire July 6, 2024National Heart, Lung and Blood Institute (NHLBI)Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI) (NOT-HL-20-814)NHLBI will accept applications for R01 projects designed to gain a better understanding of host resilience as a critical determinant of outcomes in acute respiratory distress syndrome/acute lung injury.
May 24, 2021National Institute of Allergy and Infectious Diseases (NIAID)Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases
(HHS-NIH-NIID-BAA2021-1)
This Broad Agency Announcement, issued by NIAID's Division of Microbiology and Infectious Diseases (DMID), offers research support specific to development of vaccine candidates, therapeutic products and sequencing-based diagnostics related to biodefense and emerging infectious diseases to include novel coronaviruses.

June 11, 2021

National Institute of Allergy and Infectious Diseases (NIAID)Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program (NOT-AI-21-002)NIAID will fund highly collaborative, multidisciplinary program project grants (P01) for research to design and develop vaccines capable of broad protection against coronaviruses.
June 4, 2021; optional letters of intent are due 30 days prior

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Environmental Health Sciences (NIEHS)

Immune Development in Early Life

U01 (RFA-AI-20-077)

U19 (RFA-AI-20-078)

Supported research for both Requests for Applications will define the mechanisms regulating the establishment, development and maintenance of immunity through childhood (from birth to <18 years of age). SARS-CoV-2 is specifically mentioned by the sponsors.
Applications accepted on a rolling basis through July 7, 2021National Institute of Allergy and Infectious Diseases (NIAID)Limited Competition Emergency Awards: Shared Personal Protective Resources for COVID-19 Related Vaccine and Treatment Clinical Trials (S10 Clinical Trial Not Allowed) (PAR-20-256)NIAID will provide Personal Protective Equipment (PPE) to directly support the needs of NIAID-funded treatment clinical trials and clinical studies on COVID-19. Eligibility is limited to recipients supported by NIAID's emergency appropriation as outlined in the announcement.
Applications accepted on a rolling basis through July 2, 2021.National Institute of Allergy and Infectious Diseases (NIAID)Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-059)NIAID replaced NOT-AI-20-034, a more open-ended NOSI, with one in which they are specifying limited interest areas as follows: 1) Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response; 2) Creation of critical reagents to support the SARS-CoV-2/COVID-19 research response; 3) Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; and 4) Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities.
First available due date is June 5, 2021; NOSI expires January 8, 2023National Institute of Allergy and Infectious Diseases (NIAID)Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI) (NOT-AI-21-008)NIAID will support studies that accelerate understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance and quality of immune responses against infectious agents including SARS-CoV-2. The ultimate goal of this knowledge will be to inform development of adjuvants and vaccine candidates or therapeutics that target complement components.
Deadlines vary by funding mechanism; this Notice expires September 8, 2021.National Institute of Allergy and Infectious Diseases (NIAID)Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)Research areas are: Studies to understand critical aspects of viral infection, replication, pathogenesis and transmission; Studies on the evolution and emergence of SARS-CoV-2 viruses; Development of diagnostic tests; Development of SARS-CoV-2 therapeutic candidates; Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection; and Development of SARS-CoV-2 vaccine candidates. NIAID will be using the Small Grant (R03), SBIR and STTR funding mechanisms.

July 15, 2021

March 15, 2022

National Institute of Allergy and Infectious Diseases (NIAID)Research on Bat Immunology (R21 Clinical Trial Not Allowed) (PAR-21-184)Noting the societal impact of the SARS-CoV-2 pandemic and the possibility of future pandemics, NIAID is seeking applications to characterize the bat immune system.
Applications due starting with the February 5, 2021 standard NIH deadline and dependent on funding mechanism selected; NOSI expires November 19, 2021National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases (NOT-AR-21-012)NIAMS will support basic, translational, pre-clinical and clinical observational research focused on COVID-19 and its intersection with rheumatic, musculoskeletal and skin diseases/conditions. Specific interests include impact of vaccination on patients with underlying diseases within the NIAMS mission, long-term disease consequences and health disparities.
Proposals may be submitted anytime until further notice; proposal review is promised within one weekNational Institute of Biomedical Imaging and Bioengineering (NIBIB)Fast-Track Program for COVID-19 Test Development and Distribution - Rapid Acceleration of Diagnostics (RADx)The goal of this program is to enable rapid production of innovative SARS-CoV-2 diagnostic tests. Both early and advanced stage projects will be supported.
Standard NIH deadlines for R01 and R21 grant mechanisms through July 16, 2023National Institute of Child Health and Human Development (NICHD)Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract (NOT-HD-20-021)NICHD is looking for cutting edge research to investigate possible effects of emerging viruses including SARS-CoV-2 on reproductive tissues and cells to better understand potential impacts in fertility that may be sex specific. Investigators may submit for Research Project (R01) or Exploratory/Developmental Research (R21) Grants.
Deadlines begin on February 5, 2021, depending on the chosen grant mechanism; this NOSI expires March 8, 2023.National Institute of Child Health and Human Development (NICHD)Notice of Special Interest: Research on Rehabilitation Needs Associated with the COVID-19 Pandemic (NOT-HD-20-031)NICHD wishes to fund research addressing the rehabilitation needs of COVID-19 survivors; better understand the impact of disruptions to rehabilitation services caused by COVID-19; and understand the social, behavioral, economic and health impacts of the COVID-19 pandemic on people with physical disabilities. Applications do not have to address all three research interests.
The initial deadline is June 5, 2021 (for R01 applications); the NOSI expires May 8, 2023.National Institute of Dental and Craniofacial Research (NIDCR)Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19) (NOT-DE-21-001)NIDCR will support studies focused on the role of oral/nasal cavity and oral manifestations related to SARS0CoV-2 and/or COVID-19 within the Institute's mission.
Applications for both types are due May 3, 2021. This NOSI will expire on May 4, 2021.National Institute of Environmental Health Sciences (NIEHS)Notice of Special Interest: NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)NIEHS will support both time-sensitive new projects and emergency competitive revisions from current grantees to study the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.
Applications accepted on rolling basis between March 15, 2021 and December 15, 2021National Institute of General Medical Sciences (NIGMS)Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling  Research on Coronavirus 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-21-019)This opportunity is available to all NIGMS-funded investigators to address one research area: Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive computational models for the spread of SARS-CoV-2 and other related infectious agents.
Applications will be accepted on a rolling basis through June 1, 2023National Institute of Mental Health (NIMH)Notice of Special Interest (NOSI): Administrative Supplements for COVID-19 Impacted NIMH Research (NOT-MH-21-120)NIMH will provide administrative supplements to cover unanticipated costs caused by the COVID-19 pandemic. Note that the sponsor will not support COVID-related research through this NOSI.
Applications will be accepted on a rolling basis through April 15, 2021.

National Institute of Mental Health (NIMH)

Other Participating Institutes:

National Institute on Aging

National Institute on Alcohol Abuse and Alcoholism

Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel CoronavirusNIMH is especially interested in research to (1) provide an evidence base for how a disrupted workforce may respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, (2) learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health and (3) address the intersection of COVID-19, mental health, and HIV treatment and prevention.
Not applicableNational Institute of Mental Health (NIMH)Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency Caused by Coronavirus 2019 (COVID-19) (NOT-MH-20-061)With the overall goal of more effective human subjects data harmonization, NIMH is offering guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes including a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus.
First deadline is June 5, 2021; NOSI expires September 8, 2022

National Institute of Mental Health (NIMH)

Other Participating Institutes:

National Institute of Child Health and Human Development (NICHD)

Notice of Special Interest: COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social and Emotional Development of Children (NOT-MH-21-225)The impact of "primary instructional setting disruptions" due to the COVID-19 pandemic on the development of children is the major focus of this NOSI. Research project grants (R01) are being offered. Pre-school and early childhood education settings and school-aged children (ages 3-12) are the target groups. Additionally, NICHD is specifically interested in COVID-19 related research on vulnerable populations.
May 5, 2021National Institute of Neurological Disorders and Stroke (NINDS)Notice of Special Interest (NOSI): Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations (NOT-NS-21-037)This NOSI is directed to current NINDS grantees with research projects addressing ADRD in humans. Supplemental awards are available for additional research about the effects of COVID-19 on the development or progression in ADRDs to include Frontotemporal Degeneration and Lewy Body Dementia (see notice for additional examples).
The NOSI opens on March 4, 2021 and expires on May 8, 2021.National Institute on Aging (NIA)Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19) (NOT-AG-21-015)NIA is interested in research to improve understanding of the behavioral, social and economic effects of the pandemic and to enhance efforts to control its spread. 
Dependent on grant mechanism chosen; NOSI expires May 7, 2023National Institute on Aging (NIA)Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration (NOT-AG-21-016)Offering Research Project (R01), Small (R03) and Exploratory/Developmental (R21) research grant mechanisms, NIA seeks applications addressing a variety of topics including: neurological/neurocognitive symptoms of SARS-CoV-2 infection in older adults (e.g., delirium); role of brain barriers in protecting neural tissue and how barriers are compromised by the virus; neurobiology of COVID-19 pathophysiology (e.g., vascular changes, neuroinflammation, acute hypoxic damage); genetic risk; drug discovery research; computational/informatics methods development; devices and wearables that can detect neurocognitive changes in older adults after recovery from COVID-19.
Optional letters of intent are due March 14, 2021 with full applications due April 14, 2021National Institute on Alcohol Abuse and Alcoholism (NIAAA)

SARS-Cov-2, COVID-19 and Consequences of Alcohol Use

RFA-AA-21-002 (R01)

RFA-AA-21-003 (R03)

RFA-AA-21-004 (R21)

These funding opportunities are designed to answer urgent, time-sensitive research on the relationships between alcohol consumption and COVID-19 related outcomes and consequences.

Applications accepted on a rolling basis from April 6, 2020 through May 1, 2021 with exception of NIA which has indicated they are withdrawing effective December 1, 2020

 

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Other Participating Institutes:

National Institute of Mental Health (NIMH)

National Institute on Aging (NIA)

Notice of Special Interest: NIH Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (NOT-AG-022)

See Notice of NIA withdrawal from this NOSI effective December 1, 2020

 

FAQ Document

This NOSI is designed to address the urgent public health need to better understand the 2019-nCoV, particularly to improve prevention of disease transmission among older adults and mitigation of disease severity/mortality in older adults with COVID-19.
Applications accepted on rolling basis through April 15, 2021National Institute on Alcohol Abuse and Alcoholism (NIAAA)Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAANIAAA is requesting applications to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.
October 5, 2020 through September 8, 2022 (dependent on specific program announcement - R01 or R21)National Institute on Deafness and Other Communication Disorders (NIDCD)Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders (NOT-DC-20-008)NIDCD will support research on COVID-19 in relation to the Institute's scientific programs: hearing, balance, taste, smell, voice, speech and language.
Applications may be submitted starting April 1, 2021 and going through March 31, 2022National Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI): Administrative Supplements for Research on Fentanyl and Derivatives (NOT-DA-21-032)NIDA is soliciting applications for administrative supplements to ongoing NIDA awards to support research on fentanyl addiction/overdose. Specific to COVID-19, NIDA will fund projects designed to 1) determine drug-drug interactions of fentanyl with medications to treat SARS-CoV-2 infection and 2) understand respiratory effects of SARS-CoV-2 infection among individuals with fentanyl addiction or overdose.
Applications accepted on rolling basis through March 31, 2022National Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Coronavirus (NOT-DA-21-041)NIDA will provide additional funding to current grantees for research relevant to COVID-19. The agency is especially interested in funding projects to collect and examine data on risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders (SUDs).
Deadlines start June 5, 2021 and run through September 7, 2024 depending on the grant mechanismNational Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain (NOT-DA-21-001)NIDA will fund projects examining the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). A specific interest area identified is research to explore the roles of glia in SUD and/or HIV interactions and how they may be influenced by SARS-CoV-2.
Deadlines start June 5, 2021 and end September 7, 2024 - depending on the chosen grant mechanism (R01, R03 and R21).National Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection (NOT-DA-21-011)The sponsor is interested in supporting research focused on individuals who smoke or vape marijuana and/or tobacco to determine 1) the risk of contracting COVID-19, 2) the effects on asymptomatic COVID-19 infected persons and 3) the course of the COVID-19 infection. This is a reissue of a previous NIDA NOSI -  NOT-DA-20-084.
Deadlines start on May 7, 2021 and go through September 7, 2024.National Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorder (NOT-DA-21-018)NIDA is seeking applications focused on long-term neurocognitive consequences of the current pandemic. Both Research Project Grants (R01) and Exploratory/Developmental Research Grants (R21) are available through this NOSI.
Deadline dependent on chosen funding mechanism; this NOSI expires September 8, 2024National Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 (NOT-DA-21-017)NIDA is seeking applications exploring the relationship between smoking or vaping marijuana, tobacco, cocaine and/or meth and long-term consequences of this use among individuals with HIV and COVID-19. Research project grants (R01), Small Grants (R03) and Exploratory/Developmental Grants (R21) are offered.
June 8, 2021
October 8, 2021
National Institute on Drug Abuse (NIDA)Notice of Clarification to PAR-19-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) (NOT-DA-20-062)NIDA has released a Notice of Clarification for this program announcement, adding an additional priority area concerning risks and outcomes associated with substance use and COVID-19 infection in the general population and among underserved populations.
Due dates begin with the May 7, 2021 application deadline and extend through September 7, 2024.National Institute on Drug Abuse (NIDA)Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders (NOT-DA-21-019)This NOSI offers Research Project Grants (R01), Small Grants (R03) and Exploratory/Developmental Research Grants (R21) to explore and develop telehealth methods and strategies to effectively reach individuals with HIV and substance use disorders.
November 17, 2021
March 17, 2022
November 17, 2022
February 17, 2023

National Institute on Minority Health and Health Disparities (NIMHD)

Other Participating NIH Components:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute on Drug Abuse (NIDA)

Health Services Research on Minority Health and Health Disparities (R01 - Clinical Trial Optional) (PAR-20-310)The sponsor is encouraging health services research efforts that will directly contribute to the improvement of minority health and/or the reduction of health disparities. Research interests include COVID-19.

Standard NIH deadlines apply; the first deadline will be October 5, 2020; the program announcement expires September 8, 2023

National Institute on Minority Health and Health Disparities (NIMHD)

Other Participating Institutes:

National Institute on Aging (NIA)

National Institute on Drug Abuse (NIDA)

National Cancer Institute (NCI)

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01 - Clinical Trial Optional) (PA-20-172)Will support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters (to include COVID-19) on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.
Applications accepted on rolling basis through May 1, 2021

National Institute on Minority Health and Health Disparities (NIMHD)

Other Participating Institutes:

National Institute on Aging (NIA)

National Institute of Mental Health (NIMH)

Notice of Special Interest: Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health DisparitiesNIMHD is soliciting research in health disparity populations to better understand: 1) how state and local policies and initiatives mitigate/exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.
Applications are due according to the NIH standard deadline schedule for R01s (note NIDA offers additional funding mechanisms), beginning with the February 5, 2021 deadline; this NOSI expires January 8, 2022.

National Institute on Minority Health and Health Disparities (NIMHD)

Other Participating NIH Components:

National Heart, Lung and Blood Institute (NHLBI)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Cancer Institute (NCI)

National Institute on Drug Abuse (NIDA)

Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake and Implementation among Populations that Experience Health Disparities (NOT-MD-21-008)

See NOT-DA-22-015 for specific NIDA interests.

NIMHD and partnering Institutes will fund community-engaged research to 1) evaluate intervention strategies to facilitate vaccination (including SARS-CoV-2) uptake in clinical and community contexts, and 2) address the barriers to increasing reach, access and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. 

NIDA has announced their participation in this effort and has issued their notice to denote the Institute's specific interest: Research addressing SARS-CoV-2 vaccine implementation among populations with current substance use disorders, particularly those from US health disparity populations.

N/ANational Institutes of Health (NIH)Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency (NOT-OD-20-118)NIH has issued a reminder relative to a number of COVID-19 Notices of Special Interest that the agency has "resources and guidance that will facilitate data harmonization and the development of robust data sharing plans."
June 9, 2021National Institutes of Health (NIH)Emergency Award: Social, Behavioral and Economic Research on COVID-19 Consortium Coordinating Center (AG-21-035)NIH plans to establish a coordinating center to support and develop research, dissemination, and various data sharing activities for social, behavioral, and economic research on COVID-19. Note there is also a companion request for applications - Emergency Awards: Social, Behavioral and Economic Research on COVID-19 Consortium (U01) (PAR-21-213) - to support research efforts (outlined below).

June 9, 2021

November 8, 2021

National Institutes of Health (NIH)

Other Participating Components:

National Institute on Aging (NIA)

National Eye Institute (NEI)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute on Minority Health and Health Disparities (NIMHD)

Office of Behavioral and Social Sciences Research (OBSSR)

Office of Research on Women's Health (ORWH)

Emergency Award: Social, Behavioral and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed) (PAR-21-213)NIH wishes to fund efforts to advance research on COVID-19, associated mitigation efforts, and how economic disruption affects health-related outcomes including indirect and secondary effects. Studies will leverage existing data from various sources with broad population coverage including underserved and vulnerable individuals. Areas of interest include behavioral/social factors contributing to SARS-CoV-2 transmission and prevention; impacts of various state and local mitigation policies; machine learning algorithms to build better prediction models of COVID-19 transmission; shifts in modes of healthcare delivery (e.g., telemedicine); school closure effects; the pandemic and mental health. This program announcement is soliciting individual population research projects that will then be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration and synergies.
This opportunity opens for applications starting February 5, 2021 and expires January 8, 2024.National Institutes of Health (NIH)Notice of Special Interest (NOSI): Academy of Finland (AKA) - National Institutes of Health (NIH) Partnership Program (NOT-OD-21-021)Designed to foster expansion of US-Finland biomedical and behavioral research collaborations, this joint research program has at least one COVID-19 related opportunity: To utilize lessons learned from cancer research for COVID-19 treatments.
April 15, 2021National Institutes of Health (NIH)Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19 (NOT-OD-21-071)The goal of this NOSI is to increase understanding of the effects of SARS-CoV-2 and the COVID-19 pandemic on maternal mental health, well-being, functioning and quality of life. These administrative supplements and competitive revisions can be requested by PIs who have active, relevant NIH grants.

July 12, 2021

National Institutes of Health (multiple Institutes and Centers)Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down syndrome for the INCLUDE Project (NOT-OD-20-129)The goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population which may be disproportionately affected by, and/or be at elevated risk for, adverse outcomes from contracting the virus. Multiple institutes and centers are participating and each have specified research objectives as listed in the Notice.
Applications accepted after May 7, 2021 depending on the grant mechanism and announcement  selected; the NOSI expires on June 8, 2024National Institutes of Health (NIH) (multiple institutes)Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (NOT-OD-21-100)One participating institute, the National Institute of Child Health and Human Development (NICHD), has included an interest in research to understand and improve adherence to COVID-19 preventive measures and/or behaviors.
Applications will be accepted according to the standard R01 deadline schedule, starting October 5, 2020; this NOSI expires May 8, 2021

National Institutes of Health (NIH)

Participating NIH Components:

National Institute of Minority Health and Health Disparities

National Institute of Mental Health

National Institute on Drug Abuse

Office of Disease Prevention

National Institute on Deafness and Other Communication Disorders

National Cancer Institute

National Library of Medicine

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)The purpose of this NOSI is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities across a range of illnesses and conditions including the novel coronavirus pandemic.
May 28, 2021National Institutes of Health (NIH)Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed) (RFA-RM-21-021)This Common Fund initiative will support research projects with the potential to develop, implement or disseminate innovative and effective interventions designed to prevent, reduce or eliminate health disparities and advance health equity. Preliminary data are not required for this competition. Multi-level intervention projects are highly encouraged. NIH indicates interest in studies related to COVID-19 disparities among others.
August 24, 2021National Institutes of Health (NIH)Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (RFA-MD-21-004)The National Institute of  Allergy and Infectious Diseases (NIAID), as a participating institute in this RFA, is interested in projects designed to understand the effects of structural racism and discrimination on health outcome following respiratory diseases including COVID-19 as well as COVID-19 vaccine uptake.
July 7, 2021National Institutes of Health, Office of the DirectorEmergency Awards: Community-Engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (U01 Clinical Trial Optional) (RFA-OD-21-008)This opportunity represents Phase II of the Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP) initiative. These Testing Research Projects will expand the scope and reach of RADx-UP testing interventions to reduce COVID-19 disparities and address scientific questions on intervention to increase access and acceptance of COVID-19 testing.
July 7, 2021National Institutes of Health, Office of the DirectorEmergency Awards: RADx-UP - Social, Ethical and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional) (RFA-OD-21-009)Through this RFA, NIH wishes to expand research to understand and address the social, ethic and behavioral implications of COVID-19 testing interventions among underserved and vulnerable populations. Studies funded under this Phase II opportunity will go beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in partnership with communities and other shareholders.
May 10, 2021National Institutes of Health, Office of the DirectorNotice of Special Interest (NOSI): Administrative Supplements for Rapid Acceleration of Diagnostics in Underserved Populations (RADx-UP) Phase I Projects to Address Vaccine Hesitancy and Uptake (NOT-OD-21-101)This opportunity is limited to current RADx-UP grantees and will allow expansion of outreach and education efforts to promote testing and increase acceptance of vaccines in underserved and vulnerable populations.
May 24, 2021National Institutes of Health, Office of the DirectorNotice of Special Interest (NOSI): Emergency Competitive Revisions for Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (Emergency Supplement - Clinical Trial Optional) (NOT-OD-21-103)This expedited funding mechanism allows NIH grantees with established community-engaged partnerships to propose innovative science to fill the gaps and address new challenges that have arisen in the nation's testing and virus mitigation efforts among underserved and vulnerable populations.

No set deadline for proposals in response to Dear Colleague Letter

National Science Foundation (NSF)Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

NSF encourages investigators to use the Rapid Response Research (RAPID) funding mechanism to address COVID-19 which allows for quick turnaround time to meet project requirements. The first step is to contact the program officer as RAPID proposals require program officer permission to submit.

NSF is also encouraging investigators to submit to existing funding opportunities such as the Ecology and Evolution of Infectious Diseases program (EEID), jointly funded by NSF, NIH, USDA and others; EEID proposals are due November 18, 2020.

Proposals for Medium projects may be submitted anytime

National Science Foundation/National Institutes of Health (and a host of other federal agencies)Cyber-Physical Systems (CPS)Core research areas of this initiative are control, data analytics and machine learning. NIH mentions supporting "development of CPS research and technology to facilitate medical treatment during a national crisis (e.g., SARS-CoV-2)" (see Section II.D.3 of the program solicitation for details).
No set deadlineNational Science Foundation (NSF)Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-2019)

NSF is inviting RAPID proposals and supplemental funding requests to existing awards to address COVID-19 challenges through data and/or software infrastructure development activities. Again, program officer permission is required prior to proposal submission.

Proposals accepted anytimeNational Science Foundation (NSF)Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels) (NSF 20-105)Noting that COVID-19 is unlikely to be the last pandemic in our lifetime, NSF is encouraging use of synthetic biology, cellular engineering, biosensing and immunoengineering as well as other approaches at the intersection of biology and engineering to address the threat of emerging infectious diseases.
July 12, 2021National Science Foundation (NSF)Trans-Atlantic Platform Recovery, Renewal and Resilience in a Post-Pandemic World (T-AP-RRR) (PD-21-188Y)This opportunity will support international teams of researchers for projects addressing key gaps in current understanding pertaining to the complex societal effects of COVID-19. Focus is on reducing inequalities and vulnerabilities; building a more resilient, inclusive and sustainable society; fostering democratic governance and participation; advancing responsible and inclusive digital innovation; and/or ensuring effective and accurate communication and media. All projects must fit within the mission of NSF's Directorate for Social, Behavioral and Economic Science. Participating countries represent four continents: Africa (Republic of South Africa), Europe (Croatia, Finland, France, Germany, Poland, Switzerland, United Kingdom), North America (Canada, USA), and South America (Brazil, Columbia). Research teams must include at least 3 participating countries and partners from both sides of the Atlantic.

November 26, 2021

Office of Research on Women's Health (ORWH) (within National Institutes of Health)Notice of Change: The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) (RFA-OD-20-168)ORWH has issued a Notice of Change for their ongoing Request for Applications (RFA) to include the influence of sex- and gender-related risk factors associated with COVID-19 disease prevalence, treatment and prevention. Studies examining health-seeking behaviors, access to health care and health care systems as related to COVID-19 are also within scope.
Required letters of intent are due February 1, 2021; invited full applications will then be due May 4, 2021.Patient-Centered Outcomes Research Institute (PCORI)Broad PCORI Funding Announcements: Addressing Disparities; Assessment of Prevention, Diagnosis and Treatment Options; Communication and Dissemination Research; and Improving Healthcare Systems (Cycle 1 2021)PCORI has designated COVID-19 as a Special Emphasis Area for their Cycle 1 2021 Broad PCORI Funding Announcement (PFA). Priority topics are management and survivorship of post-acute COVID-19; impact of COVID-19 on disproportionately affected populations; and impact of COVID-19-related social isolation and loneliness on health outcomes.
Required Letters of Intent due June 1, 2021; invited full applications will then be due August 31, 2021Patient-Centered Outcomes Research Institute (PCORI)Broad PCORI Funding Announcements: Addressing Disparities; Assessment of Prevention, Diagnosis and Treatment Options; Communication and Dissemination Research; and Improving Healthcare Systems (Cycle 2 2021)PCORI continues to support COVID-19 related research in their Cycle 2 2021 Broad PCORI Funding Announcement. Designating COVID-19 as a Special Emphasis Area, priority topics are management and survivorship of post-acute COVID-19; impact of COVID-19 on disproportionately affected populations; and impact of COVID-19-related social isolation and loneliness on health outcomes.
May 24, 2021Patient-Centered Outcomes Research Institute (PCORI)Engagement Award Special Cycle: Building Capacity for PCOR/CER for Topics Related to COVID-19This opportunity is a research support - not research as the sponsor emphasizes - special funding opportunity. PCORI Engagement Awards are designed to encourage active, meaningful involvement of patients, caregivers, clinicians and other healthcare stakeholders in patient-centered outcomes research/comparative clinical effectiveness efforts. For this opportunity, topics of interest are: Long-term effects of post-acute COVID-19; impact of COVID-19 on disproportionately affected populations; impact of COVID-19 on social isolation and loneliness; and engaging, educating and promoting informed decision-making around COVID-19 vaccines.
May 4, 2021Patient-Centered Outcomes Research Institute (PCORI)Increasing COVID-19 Vaccine Confidence among Long-Term Care Workers: Expedited COVID-19 Targeted PCORI Funding AnnouncementPCORI has opened their competition designed to answer the research question, "What interventions are effective in increasing COVID-19 vaccine confidence and uptake among Long-Term Care (LTC) Workers?" 
None listedPfizerCOVID-19 Vaccine GrantsThrough their Global Medical Grants Program, Pfizer is implementing their COVID-19 Vaccine Grants in phases. Current interest areas are: 1) Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations; 2) Epidemiological studies evaluating direct and indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific populations; and 3) Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.

Letters of Interest Due April 23, 2021; July 19, 2021; October 22, 2021

Full Applications Due May 14, 2021; August 13, 2021; November 12, 2021

RADx-UP* Coordination and Data Collection Center (CDCC) [NIH-funded]

[*Rapid Acceleration of Diagnostics for Underserved Populations]

RADx-UP* CDCC Rapid Research Pilot ProgramApplicants to this pilot project program should address potential challenges to increased COVID-19 testing in underserved and vulnerable populations in three key areas: 1) Identify and address potential barriers, 2) Align testing to the target population and 3) Test workflow and access. A community-engagement approach should be used.
May 4, 2021 - deadline for required Letters of InquiryRussell Sage FoundationResearch GrantsThe Foundation's core programs are Future of Work; Immigration and Immigrant Integration; Race, Ethnicity and Immigration; Social, Political and Economic Inequality. Within these core programs, applicants may address this topic: Research on the COVID-19 pandemic and the resulting recession in the US.
Required letters of intent are due July 28, 2021; invited full proposals will then be due September 22, 2021.Tinker FoundationInstitutional Grants: Education ProgramThe Foundation's overall goal is to support changes to policy and practice that improve the lives of Latin Americans. They have implemented a special initiative related to their Education Program - Ensuring Educational Equity During the Covid-19 Pandemic.
June 4, 2021US Department of Agriculture Rural Utilities ServiceDistance Learning and Telemedicine GrantsIn this Fiscal Year 2021 solicitation, USDA will fund projects concerning containment of the COVID-19 pandemic among other topics. The ultimate goal of this program is to increase rural access to distance learning and telemedicine.